Protagonist Therapeutics Inc (PTGX)

39.57 +0.59 (+1.51%) USD  |  NASDAQ  |  Jan 03, 16:00
39.63 +0.06 (+0.15%) After-Hours: 20:00
More

Protagonist Therapeutics Research and Development Expense (Annual): 120.16M for Dec. 31, 2023

Research and Development Expense (Annual) Chart

View Research and Development Expense (Annual) for PTGX.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Research and Development Expense (Annual) Chart
Start Trial

Historical Data

View Historical Data
Start Trial

R&D Expense Definition

View R&D Expense Definition
Start Trial

R&D expense is a line item from many companies' income statements.

Read full definition.

Research and Development Expense (Annual) Range, Past 5 Years

View Research and Development Expense (Annual) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Research and Development Expense (Annual) Benchmarks

View Research and Development Expense (Annual) Benchmarks
Start Trial
Assembly Biosciences Inc 48.90M
Precision BioSciences Inc 53.38M
Entrada Therapeutics Inc 99.88M
NovaBay Pharmaceuticals Inc 0.068M
Palatin Technologies Inc 22.40M